Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis.
Use of menopausal hormone therapy (HT) has been associated with reduced risk of colorectal cancer; evidence for its effect on other gastrointestinal cancers is limited. We conducted a nested case-control study within a UK cohort, and meta-analyses combining our results with those from published stud...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1797073971800178688 |
|---|---|
| author | Green, J Czanner, G Reeves, G Watson, J Wise, L Roddam, A Beral, V |
| author_facet | Green, J Czanner, G Reeves, G Watson, J Wise, L Roddam, A Beral, V |
| author_sort | Green, J |
| collection | OXFORD |
| description | Use of menopausal hormone therapy (HT) has been associated with reduced risk of colorectal cancer; evidence for its effect on other gastrointestinal cancers is limited. We conducted a nested case-control study within a UK cohort, and meta-analyses combining our results with those from published studies. Our study included women aged 50+ in the UK General Practice Research Database (GPRD): 1,054 with oesophageal, 750 with gastric and 4,708 with colorectal cancer, and 5 age- and practice-matched controls per case. Relative risks (RRs) and 95% confidence intervals (CIs) for cancer in relation to prospectively-recorded HT prescriptions were estimated by conditional logistic regression. Women prescribed HT had a reduced risk of oesophageal cancer (adjusted RR for 1+ vs. no HT prescriptions, 0.68, 95% CI 0.53-0.88; p = 0.004), gastric cancer (0.75, 0.54-1.05; p = 0.1) and colorectal cancer (0.81, 0.73-0.90; p < 0.001). There were no significant differences in cancer risk by HT type, estimated duration of HT use or between past and current users. In meta-analyses, risks for ever vs. never use of HT were significantly reduced for all three cancers (summary RR for oesophageal cancer, 0.68, 0.55-0.84, p < 0.001; for gastric cancer, 0.78, 0.65-0.94, p = 0.008; for colorectal cancer, 0.84, 0.81-0.88, p < 0.001). In high-income countries, estimated incidence over 5 years of these three cancers combined in women aged 50-64 was 2.9/1,000 in HT users and 3.6/1,000 in never users. The absolute reduction in risk of these cancers in HT users is small compared to the HT-associated increased risk of breast cancer. |
| first_indexed | 2024-03-06T23:29:35Z |
| format | Journal article |
| id | oxford-uuid:6b8fe705-9a08-4d2f-8e53-61b593e93d8b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:29:35Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:6b8fe705-9a08-4d2f-8e53-61b593e93d8b2022-03-26T19:04:56ZMenopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6b8fe705-9a08-4d2f-8e53-61b593e93d8bEnglishSymplectic Elements at Oxford2012Green, JCzanner, GReeves, GWatson, JWise, LRoddam, ABeral, VUse of menopausal hormone therapy (HT) has been associated with reduced risk of colorectal cancer; evidence for its effect on other gastrointestinal cancers is limited. We conducted a nested case-control study within a UK cohort, and meta-analyses combining our results with those from published studies. Our study included women aged 50+ in the UK General Practice Research Database (GPRD): 1,054 with oesophageal, 750 with gastric and 4,708 with colorectal cancer, and 5 age- and practice-matched controls per case. Relative risks (RRs) and 95% confidence intervals (CIs) for cancer in relation to prospectively-recorded HT prescriptions were estimated by conditional logistic regression. Women prescribed HT had a reduced risk of oesophageal cancer (adjusted RR for 1+ vs. no HT prescriptions, 0.68, 95% CI 0.53-0.88; p = 0.004), gastric cancer (0.75, 0.54-1.05; p = 0.1) and colorectal cancer (0.81, 0.73-0.90; p < 0.001). There were no significant differences in cancer risk by HT type, estimated duration of HT use or between past and current users. In meta-analyses, risks for ever vs. never use of HT were significantly reduced for all three cancers (summary RR for oesophageal cancer, 0.68, 0.55-0.84, p < 0.001; for gastric cancer, 0.78, 0.65-0.94, p = 0.008; for colorectal cancer, 0.84, 0.81-0.88, p < 0.001). In high-income countries, estimated incidence over 5 years of these three cancers combined in women aged 50-64 was 2.9/1,000 in HT users and 3.6/1,000 in never users. The absolute reduction in risk of these cancers in HT users is small compared to the HT-associated increased risk of breast cancer. |
| spellingShingle | Green, J Czanner, G Reeves, G Watson, J Wise, L Roddam, A Beral, V Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. |
| title | Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. |
| title_full | Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. |
| title_fullStr | Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. |
| title_full_unstemmed | Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. |
| title_short | Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. |
| title_sort | menopausal hormone therapy and risk of gastrointestinal cancer nested case control study within a prospective cohort and meta analysis |
| work_keys_str_mv | AT greenj menopausalhormonetherapyandriskofgastrointestinalcancernestedcasecontrolstudywithinaprospectivecohortandmetaanalysis AT czannerg menopausalhormonetherapyandriskofgastrointestinalcancernestedcasecontrolstudywithinaprospectivecohortandmetaanalysis AT reevesg menopausalhormonetherapyandriskofgastrointestinalcancernestedcasecontrolstudywithinaprospectivecohortandmetaanalysis AT watsonj menopausalhormonetherapyandriskofgastrointestinalcancernestedcasecontrolstudywithinaprospectivecohortandmetaanalysis AT wisel menopausalhormonetherapyandriskofgastrointestinalcancernestedcasecontrolstudywithinaprospectivecohortandmetaanalysis AT roddama menopausalhormonetherapyandriskofgastrointestinalcancernestedcasecontrolstudywithinaprospectivecohortandmetaanalysis AT beralv menopausalhormonetherapyandriskofgastrointestinalcancernestedcasecontrolstudywithinaprospectivecohortandmetaanalysis |